ASH 2018 | Targeting JAK2 V617F in MPNs with interferon alpha and arsenic trioxide
Jean-Jacques Kiladjian
• 6 Dec 2018
From the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the combination of interferon and arsenic trioxide to target JAK2 V617F in myeloproliferative neoplasms (MPNs). Promising preclinical results have been seen, showing specific and synergistric targeting of the mutation.
